MediWound (MediWound) 3-Year EBITDA Growth Rate : 34.50% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is MediWound 3-Year EBITDA Growth Rate?

MediWound's EBITDA per Share for the three months ended in Dec. 2023 was $0.61.

During the past 3 years, the average EBITDA Per Share Growth Rate was 34.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of MediWound was 45.10% per year. The lowest was -64.50% per year. And the median was 13.90% per year.

Competitive Comparison of MediWound's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, MediWound's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MediWound's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MediWound's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where MediWound's 3-Year EBITDA Growth Rate falls into.

MediWound 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

MediWound (NAS:MDWD) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

MediWound 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of MediWound's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

MediWound (MediWound) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediWound Ltd (NAS:MDWD) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

M8W:Germany

Address

42 Hayarkon Street, Yavne, ISR, 8122745

Website

https://www.mediwound.com

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. Its first biopharmaceutical product, NexoBrid removes dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns also referred to as severe burns. NexoBrid is currently in clinical development in North America and is in the process of preparing its Biologics License Application. The company derives its revenue from the United States.